Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections.
Identifieur interne : 001470 ( PubMed/Corpus ); précédent : 001469; suivant : 001471Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections.
Auteurs : Alimuddin Zumla ; Esam I. Azhar ; Yaseen Arabi ; Badriah Alotaibi ; Martin Rao ; Brian Mccloskey ; Eskild Petersen ; Markus MaeurerSource :
- International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [ 1878-3511 ] ; 2015.
English descriptors
- KwdEn :
- Adult, Antiviral Agents (therapeutic use), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Cross Infection (epidemiology), Disease Outbreaks, Humans, Immunocompromised Host, Lung, Middle East Respiratory Syndrome Coronavirus, Republic of Korea, Saudi Arabia (epidemiology), Treatment Outcome.
- MESH :
- chemical , therapeutic use : Antiviral Agents.
- drug therapy : Coronavirus Infections.
- epidemiology : Coronavirus Infections, Cross Infection, Saudi Arabia.
- Adult, Disease Outbreaks, Humans, Immunocompromised Host, Lung, Middle East Respiratory Syndrome Coronavirus, Republic of Korea, Treatment Outcome.
Abstract
Three years after its first discovery in Jeddah Saudi Arabia, the novel zoonotic pathogen of humans, the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) continues to be a major threat to global health security.(1) Sporadic community acquired cases of MERS continue to be reported from the Middle East. The recent nosocomial outbreaks in hospitals in Seoul, Korea and at the National Guard Hospital in Riyadh, Saudi Arabia indicate the epidemic potential of MERS-CoV. Currently there are no effective anti-MERS-CoV anti-viral agents or therapeutics and MERS is associated with a high mortality rate (40%) in hospitalised patients. A large proportion of MERS patients who die have a range of pulmonary pathology ranging from pneumonia to adult respiratory distress syndrome with multi-organ failure, compounded by co-morbidities, reflecting a precarious balance of interactions between the host-immune system and MERS-CoV. Whilst we wait for new MERS-CoV specific drugs, therapeutics and vaccines to be developed, there is a need to advance a range of Host-Directed Therapies. A range of HDTs are available, including commonly used drugs with good safety profiles, which could augment host innate and adaptive immune mechanisms to MERS-CoV, modulate excessive inflammation and reduce lung tissue destruction. We discuss the rationale and potential of using Host-Directed Therapies for improving the poor treatment outcomes associated with MERS. Carefully designed randomized controlled trials will be needed to determine whether HDTs could benefit patients with MERS. The recurrent outbreaks of MERS-CoV infections at hospitals in the Middle East present unique opportunities to conduct randomized clinical trials. The time has come for a more coordinated global response to MERS and a multidisciplinary global MERS-CoV response group is required to take forward priority research agendas.
DOI: 10.1016/j.ijid.2015.09.005
PubMed: 26365771
Links to Exploration step
pubmed:26365771Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections.</title><author><name sortKey="Zumla, Alimuddin" sort="Zumla, Alimuddin" uniqKey="Zumla A" first="Alimuddin" last="Zumla">Alimuddin Zumla</name><affiliation><nlm:affiliation>Division of Infection and Immunity, University College London, and NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, United Kingdom; Special Infectious Agents Unit, King Fahd Medical Research Centre, and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia. Electronic address: a.zumla@ucl.ac.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Azhar, Esam I" sort="Azhar, Esam I" uniqKey="Azhar E" first="Esam I" last="Azhar">Esam I. Azhar</name><affiliation><nlm:affiliation>Special Infectious Agents Unit, King Fahd Medical Research Centre, and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia. Electronic address: eazhar@kau.edu.sa.</nlm:affiliation></affiliation></author><author><name sortKey="Arabi, Yaseen" sort="Arabi, Yaseen" uniqKey="Arabi Y" first="Yaseen" last="Arabi">Yaseen Arabi</name><affiliation><nlm:affiliation>Intensive Care Department, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, 11426, Kingdom of Saudi Arabia. Electronic address: arabi@ngha.med.sa.</nlm:affiliation></affiliation></author><author><name sortKey="Alotaibi, Badriah" sort="Alotaibi, Badriah" uniqKey="Alotaibi B" first="Badriah" last="Alotaibi">Badriah Alotaibi</name><affiliation><nlm:affiliation>Global Center for Mass Gatherings Medicine, Ministry of Health, Riyadh, Kingdom of Saudi Arabia. Electronic address: otaibi_b1@yahoo.com.</nlm:affiliation></affiliation></author><author><name sortKey="Rao, Martin" sort="Rao, Martin" uniqKey="Rao M" first="Martin" last="Rao">Martin Rao</name><affiliation><nlm:affiliation>Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, and Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden. Electronic address: martin.rao@ki.se.</nlm:affiliation></affiliation></author><author><name sortKey="Mccloskey, Brian" sort="Mccloskey, Brian" uniqKey="Mccloskey B" first="Brian" last="Mccloskey">Brian Mccloskey</name><affiliation><nlm:affiliation>Global Health Department, Public Health England, London, United Kingdom. Electronic address: Brian.McCloskey@phe.gov.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Petersen, Eskild" sort="Petersen, Eskild" uniqKey="Petersen E" first="Eskild" last="Petersen">Eskild Petersen</name><affiliation><nlm:affiliation>Department of Infectious Diseases and Clinical Microbiology, Aarhus University Hospital Skejby, Aarhus, Denmark. Electronic address: eskildp@dadlnet.dk.</nlm:affiliation></affiliation></author><author><name sortKey="Maeurer, Markus" sort="Maeurer, Markus" uniqKey="Maeurer M" first="Markus" last="Maeurer">Markus Maeurer</name><affiliation><nlm:affiliation>Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, and Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden. Electronic address: Markus.Maeurer@ki.se.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26365771</idno><idno type="pmid">26365771</idno><idno type="doi">10.1016/j.ijid.2015.09.005</idno><idno type="wicri:Area/PubMed/Corpus">001470</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001470</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections.</title><author><name sortKey="Zumla, Alimuddin" sort="Zumla, Alimuddin" uniqKey="Zumla A" first="Alimuddin" last="Zumla">Alimuddin Zumla</name><affiliation><nlm:affiliation>Division of Infection and Immunity, University College London, and NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, United Kingdom; Special Infectious Agents Unit, King Fahd Medical Research Centre, and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia. Electronic address: a.zumla@ucl.ac.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Azhar, Esam I" sort="Azhar, Esam I" uniqKey="Azhar E" first="Esam I" last="Azhar">Esam I. Azhar</name><affiliation><nlm:affiliation>Special Infectious Agents Unit, King Fahd Medical Research Centre, and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia. Electronic address: eazhar@kau.edu.sa.</nlm:affiliation></affiliation></author><author><name sortKey="Arabi, Yaseen" sort="Arabi, Yaseen" uniqKey="Arabi Y" first="Yaseen" last="Arabi">Yaseen Arabi</name><affiliation><nlm:affiliation>Intensive Care Department, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, 11426, Kingdom of Saudi Arabia. Electronic address: arabi@ngha.med.sa.</nlm:affiliation></affiliation></author><author><name sortKey="Alotaibi, Badriah" sort="Alotaibi, Badriah" uniqKey="Alotaibi B" first="Badriah" last="Alotaibi">Badriah Alotaibi</name><affiliation><nlm:affiliation>Global Center for Mass Gatherings Medicine, Ministry of Health, Riyadh, Kingdom of Saudi Arabia. Electronic address: otaibi_b1@yahoo.com.</nlm:affiliation></affiliation></author><author><name sortKey="Rao, Martin" sort="Rao, Martin" uniqKey="Rao M" first="Martin" last="Rao">Martin Rao</name><affiliation><nlm:affiliation>Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, and Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden. Electronic address: martin.rao@ki.se.</nlm:affiliation></affiliation></author><author><name sortKey="Mccloskey, Brian" sort="Mccloskey, Brian" uniqKey="Mccloskey B" first="Brian" last="Mccloskey">Brian Mccloskey</name><affiliation><nlm:affiliation>Global Health Department, Public Health England, London, United Kingdom. Electronic address: Brian.McCloskey@phe.gov.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Petersen, Eskild" sort="Petersen, Eskild" uniqKey="Petersen E" first="Eskild" last="Petersen">Eskild Petersen</name><affiliation><nlm:affiliation>Department of Infectious Diseases and Clinical Microbiology, Aarhus University Hospital Skejby, Aarhus, Denmark. Electronic address: eskildp@dadlnet.dk.</nlm:affiliation></affiliation></author><author><name sortKey="Maeurer, Markus" sort="Maeurer, Markus" uniqKey="Maeurer M" first="Markus" last="Maeurer">Markus Maeurer</name><affiliation><nlm:affiliation>Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, and Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden. Electronic address: Markus.Maeurer@ki.se.</nlm:affiliation></affiliation></author></analytic><series><title level="j">International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</title><idno type="eISSN">1878-3511</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antiviral Agents (therapeutic use)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (epidemiology)</term><term>Cross Infection (epidemiology)</term><term>Disease Outbreaks</term><term>Humans</term><term>Immunocompromised Host</term><term>Lung</term><term>Middle East Respiratory Syndrome Coronavirus</term><term>Republic of Korea</term><term>Saudi Arabia (epidemiology)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Cross Infection</term><term>Saudi Arabia</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Disease Outbreaks</term><term>Humans</term><term>Immunocompromised Host</term><term>Lung</term><term>Middle East Respiratory Syndrome Coronavirus</term><term>Republic of Korea</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Three years after its first discovery in Jeddah Saudi Arabia, the novel zoonotic pathogen of humans, the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) continues to be a major threat to global health security.(1) Sporadic community acquired cases of MERS continue to be reported from the Middle East. The recent nosocomial outbreaks in hospitals in Seoul, Korea and at the National Guard Hospital in Riyadh, Saudi Arabia indicate the epidemic potential of MERS-CoV. Currently there are no effective anti-MERS-CoV anti-viral agents or therapeutics and MERS is associated with a high mortality rate (40%) in hospitalised patients. A large proportion of MERS patients who die have a range of pulmonary pathology ranging from pneumonia to adult respiratory distress syndrome with multi-organ failure, compounded by co-morbidities, reflecting a precarious balance of interactions between the host-immune system and MERS-CoV. Whilst we wait for new MERS-CoV specific drugs, therapeutics and vaccines to be developed, there is a need to advance a range of Host-Directed Therapies. A range of HDTs are available, including commonly used drugs with good safety profiles, which could augment host innate and adaptive immune mechanisms to MERS-CoV, modulate excessive inflammation and reduce lung tissue destruction. We discuss the rationale and potential of using Host-Directed Therapies for improving the poor treatment outcomes associated with MERS. Carefully designed randomized controlled trials will be needed to determine whether HDTs could benefit patients with MERS. The recurrent outbreaks of MERS-CoV infections at hospitals in the Middle East present unique opportunities to conduct randomized clinical trials. The time has come for a more coordinated global response to MERS and a multidisciplinary global MERS-CoV response group is required to take forward priority research agendas. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">26365771</PMID><DateCompleted><Year>2016</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3511</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><PubDate><Year>2015</Year><Month>Nov</Month></PubDate></JournalIssue><Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title><ISOAbbreviation>Int. J. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections.</ArticleTitle><Pagination><MedlinePgn>71-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijid.2015.09.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1201-9712(15)00215-5</ELocationID><Abstract><AbstractText>Three years after its first discovery in Jeddah Saudi Arabia, the novel zoonotic pathogen of humans, the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) continues to be a major threat to global health security.(1) Sporadic community acquired cases of MERS continue to be reported from the Middle East. The recent nosocomial outbreaks in hospitals in Seoul, Korea and at the National Guard Hospital in Riyadh, Saudi Arabia indicate the epidemic potential of MERS-CoV. Currently there are no effective anti-MERS-CoV anti-viral agents or therapeutics and MERS is associated with a high mortality rate (40%) in hospitalised patients. A large proportion of MERS patients who die have a range of pulmonary pathology ranging from pneumonia to adult respiratory distress syndrome with multi-organ failure, compounded by co-morbidities, reflecting a precarious balance of interactions between the host-immune system and MERS-CoV. Whilst we wait for new MERS-CoV specific drugs, therapeutics and vaccines to be developed, there is a need to advance a range of Host-Directed Therapies. A range of HDTs are available, including commonly used drugs with good safety profiles, which could augment host innate and adaptive immune mechanisms to MERS-CoV, modulate excessive inflammation and reduce lung tissue destruction. We discuss the rationale and potential of using Host-Directed Therapies for improving the poor treatment outcomes associated with MERS. Carefully designed randomized controlled trials will be needed to determine whether HDTs could benefit patients with MERS. The recurrent outbreaks of MERS-CoV infections at hospitals in the Middle East present unique opportunities to conduct randomized clinical trials. The time has come for a more coordinated global response to MERS and a multidisciplinary global MERS-CoV response group is required to take forward priority research agendas. </AbstractText><CopyrightInformation>Copyright © 2015. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zumla</LastName><ForeName>Alimuddin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Infection and Immunity, University College London, and NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, United Kingdom; Special Infectious Agents Unit, King Fahd Medical Research Centre, and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia. Electronic address: a.zumla@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azhar</LastName><ForeName>Esam I</ForeName><Initials>EI</Initials><AffiliationInfo><Affiliation>Special Infectious Agents Unit, King Fahd Medical Research Centre, and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia. Electronic address: eazhar@kau.edu.sa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arabi</LastName><ForeName>Yaseen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Intensive Care Department, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, 11426, Kingdom of Saudi Arabia. Electronic address: arabi@ngha.med.sa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alotaibi</LastName><ForeName>Badriah</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Global Center for Mass Gatherings Medicine, Ministry of Health, Riyadh, Kingdom of Saudi Arabia. Electronic address: otaibi_b1@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, and Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden. Electronic address: martin.rao@ki.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCloskey</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Global Health Department, Public Health England, London, United Kingdom. Electronic address: Brian.McCloskey@phe.gov.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Eskild</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Clinical Microbiology, Aarhus University Hospital Skejby, Aarhus, Denmark. Electronic address: eskildp@dadlnet.dk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maeurer</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, and Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden. Electronic address: Markus.Maeurer@ki.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Int J Infect Dis</MedlineTA><NlmUniqueID>9610933</NlmUniqueID><ISSNLinking>1201-9712</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003428" MajorTopicYN="N">Cross Infection</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016867" MajorTopicYN="N">Immunocompromised Host</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065207" MajorTopicYN="Y">Middle East Respiratory Syndrome Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N">Republic of Korea</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012529" MajorTopicYN="N">Saudi Arabia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26365771</ArticleId><ArticleId IdType="pii">S1201-9712(15)00215-5</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2015.09.005</ArticleId><ArticleId IdType="pmc">PMC7128983</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Clin Microbiol Rev. 2015 Apr;28(2):465-522</Citation><ArticleIdList><ArticleId IdType="pubmed">25810418</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Infect Dis. 2015 Nov 1;61(9):1432-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26219693</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2013 Sep;13(9):752-61</Citation><ArticleIdList><ArticleId IdType="pubmed">23891402</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int J Infect Dis. 2014 Jun;23:63-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24699184</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2014 Feb;88(3):1834-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24257613</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int J Infect Dis. 2014 Dec;29:301-6</Citation><ArticleIdList><ArticleId IdType="pubmed">25303830</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell. 2010 Mar 19;140(6):935-50</Citation><ArticleIdList><ArticleId IdType="pubmed">20303881</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Allergy Clin Immunol. 2004 Nov;114(5):1059-69</Citation><ArticleIdList><ArticleId IdType="pubmed">15536411</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2014 Nov;14(11):1090-1095</Citation><ArticleIdList><ArticleId IdType="pubmed">25278221</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93</Citation><ArticleIdList><ArticleId IdType="pubmed">24841273</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>AIDS. 2013 May 15;27(8):1283-93</Citation><ArticleIdList><ArticleId IdType="pubmed">23925377</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int J Antimicrob Agents. 2014 Dec;44(6):528-32</Citation><ArticleIdList><ArticleId IdType="pubmed">25288266</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Opin Pulm Med. 2014 May;20(3):233-41</Citation><ArticleIdList><ArticleId IdType="pubmed">24626235</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2011;6(7):e22572</Citation><ArticleIdList><ArticleId IdType="pubmed">21818340</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2011 May;85(9):4234-45</Citation><ArticleIdList><ArticleId IdType="pubmed">21325418</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2010 Dec 18;376(9758):2116</Citation><ArticleIdList><ArticleId IdType="pubmed">21168053</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cancer Res. 2010 Jun 15;70(12):4850-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20501849</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cancer J. 2014 Mar-Apr;20(2):119-22</Citation><ArticleIdList><ArticleId IdType="pubmed">24667956</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2013 Jun 27;368(26):2487-94</Citation><ArticleIdList><ArticleId IdType="pubmed">23718156</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Pathol. 2015 Jan;235(2):175-84</Citation><ArticleIdList><ArticleId IdType="pubmed">25294366</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int J Infect Dis. 2015 Oct;39:7-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26275845</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int J Infect Dis. 2015 Jul;36:54-5</Citation><ArticleIdList><ArticleId IdType="pubmed">26072036</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2014 Jan 15;209(2):173-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24218505</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2014 Nov;14(11):1136-1149</Citation><ArticleIdList><ArticleId IdType="pubmed">25189352</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Exp Ther Med. 2015 May;9(5):1813-1818</Citation><ArticleIdList><ArticleId IdType="pubmed">26136898</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Respir Med. 2014 Feb;2(2):108-22</Citation><ArticleIdList><ArticleId IdType="pubmed">24503266</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2013 Sep;99(3):417-35</Citation><ArticleIdList><ArticleId IdType="pubmed">23831494</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Respir Med. 2015 Jan;3(1):24-32</Citation><ArticleIdList><ArticleId IdType="pubmed">25529339</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Transbound Emerg Dis. 2016 Dec;63(6):602-620</Citation><ArticleIdList><ArticleId IdType="pubmed">25644240</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Drug Discov. 2015 Aug;14(8):511-2</Citation><ArticleIdList><ArticleId IdType="pubmed">26184493</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int J Infect Dis. 2014 Mar;20:42-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24406736</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Arterioscler Thromb Vasc Biol. 2015 May;35(5):1071-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25814671</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunother. 2005 Nov-Dec;28(6):517-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16224268</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect. 2013 Dec;67(6):606-16</Citation><ArticleIdList><ArticleId IdType="pubmed">24096239</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Ann Intern Med. 2014 Mar 18;160(6):389-97</Citation><ArticleIdList><ArticleId IdType="pubmed">24474051</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int J Infect Dis. 2015 Sep;38:65-7</Citation><ArticleIdList><ArticleId IdType="pubmed">26216766</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Rep. 2013;3:1686</Citation><ArticleIdList><ArticleId IdType="pubmed">23594967</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Pulm Circ. 2012 Oct;2(4):397-406</Citation><ArticleIdList><ArticleId IdType="pubmed">23372924</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Antimicrob Chemother. 2015 Jul;70(7):2129-32</Citation><ArticleIdList><ArticleId IdType="pubmed">25900158</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2013 Aug 1;369(5):407-16</Citation><ArticleIdList><ArticleId IdType="pubmed">23782161</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84</Citation><ArticleIdList><ArticleId IdType="pubmed">24841269</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Ann Intern Med. 2015 Oct 6;163(7):519-28</Citation><ArticleIdList><ArticleId IdType="pubmed">26258555</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Respir Med. 2015 Jul;3(7):509-10</Citation><ArticleIdList><ArticleId IdType="pubmed">26050550</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Curr. 2013 Nov 12;5:</Citation><ArticleIdList><ArticleId IdType="pubmed">24270606</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2015 Feb;59(2):1088-99</Citation><ArticleIdList><ArticleId IdType="pubmed">25487801</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antivir Ther. 2015;20(1):87-91</Citation><ArticleIdList><ArticleId IdType="pubmed">24831606</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2013 Mar 28;368(13):1251-5</Citation><ArticleIdList><ArticleId IdType="pubmed">23534565</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Am J Respir Crit Care Med. 2008 Jul 15;178(2):168-79</Citation><ArticleIdList><ArticleId IdType="pubmed">18436790</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001470 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001470 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26365771
|texte= Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26365771" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |